17 stories found
New weight-loss medications, including Pfizer's experimental shot and Boehringer's obesity drug, are showing promising results in trials for significant weight reduction and fat loss, with some even suggesting a slowdown in biological aging. However, these drugs can also cause debilitating side effects, as detailed by actress Mayim Bialik, highlighting the ongoing discussion about their risks and benefits.
Late-stage trial results for Boehringer Ingelheim's obesity drug indicate that it helps patients lose fat rather than muscle, a key finding for weight-loss treatments.
Boehringer Ingelheim announced promising study results for its weight-loss drug, Survodutid, which has increased the company's optimism for its potential market approval. This marks a significant step
Pharmaceutical manufacturers are facing a potential helium shortage, with current supplies lasting only four to eight weeks, due to disruptions related to the Strait of Hormuz. While Merck does not anticipate immediate bottlenecks, Boehringer is seeking to reduce its reliance on helium imports.
Pia Schall, CEO of Boehringer Ingelheim in Poland, emphasizes that high-quality healthcare and disease prevention are crucial not only for patient well-being but also for stable economic development.
Boehringer Ingelheim, recognized as a top employer, details its integrated strategy for developing and supporting a diverse workforce and creating leadership opportunities.
Pharmaceutical giants Lilly and Boehringer Ingelheim have announced they are stopping millions in investments in Germany. This decision comes in response to the new GKV (Statutory Health Insurance) law.
Zealand Pharma announced that its GLP-1 drug, developed in collaboration with Boehringer Ingelheim, achieved an average of 17% weight loss in participants during a late-stage clinical trial.
Boehringer Ingelheim says pricing regime hinders access to treatments as group touts liver benefits from weight-loss drug
Boehringer Ingelheim is expanding its investment in computational innovation by establishing a new AI Accelerator in the UK's Knowledge Quarter.
Ensuring high-quality healthcare is crucial not only for patient well-being but also for the stable development of the economy, according to Pia Schall, General Director of Boehringer Ingelheim in Poland.
Boehringer's Hernexeos was one of the 18 drugs selected so far for the FDA Commissioner's National Priority Voucher Program that allows speedy process and cuts the review time to one to two months from the typical 10 to 12 months
Η Boehringer Ingelheim Hellas συμμετέχει και φέτος ως Χρυσός Χορηγός στην 11η εκστρατεία της ΑΜΚΕ «Με Οδηγό τον Διαβήτη», στηρίζοντας μια πρωτοβουλία που προσφέρει δωρεάν υπηρεσίες υγείας και…
A drug developed by Boehringer Ingelheim and Zealand Pharma demonstrated an average of 16.6% weight loss in patients during a late-stage clinical trial, indicating potential for obesity treatment.
A new study conducted by UNED, in collaboration with Boehringer Ingelheim, reveals that over 65% of veterinarians have considered leaving their profession due to excessive pressure. The research, released on World Veterinary Day, highlights the significant challenges faced by veterinarians.
Boehringer has handed over $50 million and market rights for Click's digital therapeutic product, indicating a significant business transaction.
Shashank Deshpande, CEO of Boehringer Ingelheim, expresses concerns about the state of pharmaceutical research in Germany, emphasizing the need for skilled minds over rare earths, and is undeterred by Trump's pricing policies or the competitive weight-loss drug market.